


CLAIMS


1. A method of treating a subject with acute myeloid leukemia or myelodysplastic syndrome, comprising administering an effective amount of Compound (I):



or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein Compound (I) is a fumarate salt.
3. The method of claim 2, wherein the molar ratio between Compound (I) and fumaric acid is 1:1.
4. The method of any one of claims 1-3, wherein the subject has acute myeloid leukemia.
5. The method of claim 4, wherein the acute myeloid leukemia is relapsed or refractory.
6. The method of any one of claims 1-5, wherein the acute myeloid leukemia is complex karyotype acute myeloid leukemia.
7. The method of any one of claims 1-6, further comprising co-administering an additional therapeutic agent.
8. The method of claim 7, wherein the additional therapeutic agent is an anti-cancer drug.
9. The method of claim 8, wherein the anti-cancer drug is Venetoclax.

10. The method of claim 8, wherein the anti-cancer drug is 5-Azacytidine.
11. The method of any one of claims 7-10, wherein Compound (I) and the additional therapeutic agent are administered concurrently.
12. The method of any one of claims 7-10, wherein Compound (I) and the additional therapeutic agent are administered sequentially.
13. The method of claim 8, wherein the anti-cancer drug is decitabine.
14. A method of treating a subject with acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, comprising administering an effective amount of Compound (I):



or a pharmaceutically acceptable salt thereof.

15. The method of claim 14, wherein Compound (I) is a fumarate salt.
16. The method of claim 15, wherein the molar ratio between Compound (I) and fumaric acid is 1:1.
17. The method of any one of claims 14-16, wherein the subject has acute lymphoblastic leukemia.
18. The method of claim 17, wherein the acute lymphoblastic leukemia is T-cell acute lymphoblastic leukemia or B-cell acute lymphoblastic leukemia.

19. The method of any one of claims 14-16, wherein the subject has chronic myeloid leukemia.
20. The method of any one of claims 14-16, wherein the subject has non-Hodgkin's lymphoma.
21. The method of any one of claims 14-16, wherein the subject has Burkitt lymphoma.
22. The method of any one of claims 14-16, wherein the subject has diffuse large B-cell lymphoma.
23. The method of claim 22, wherein the diffuse large B-cell lymphoma is germinal center B cell-like or activated B cell-like.
24. The method of any one of claims 14-23, wherein the acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma is relapsed or refractory.
25. The method of any one of claims 14-24, wherein the acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma is complex karyotype.
26. The method of any one of claims 14-25, further comprising co-administering an additional therapeutic agent.
27. The method of claim 26, wherein the additional therapeutic agent is an anti-cancer drug.
28. The method of claim 27, wherein the anti-cancer drug is Venetoclax, 5-Azacytidine, or decitabine.
29. The method of any one of claims 26-28, wherein Compound (I) and the additional therapeutic agent are administered concurrently or sequentially.